

Amikacin

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Antituberculosis medicines

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

Neutropenia (high-risk)

co-prescribed with cefotaxime

Inflammatory and other diseases of prostate (severe)

co-prescribed with cefotaxime

Acute pyelonephritis (severe)

co-prescribed with ceftriaxone

Inflammatory and other diseases of prostate (severe)

co-prescribed with ceftriaxone

Acute pyelonephritis (severe)

Multi-drug resistant Mycobacterium tuberculosis

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid ◦ Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection ◦ Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate) ◦ Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate) ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid ◦ Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)	First choice Acute pharyngitis Periapical abscess without sinus Acute sinusitis Acute otitis media Chronic obstructive pulmonary disease with acute exacerbation Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with gentamicin Sepsis without septic shock Second choice Bacterial meningitis Other indications Bacterial infection of unspecified site Infectious cystitis

Amoxicillin + clavulanic acid

Section

Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Antituberculosis medicines

- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

First choice

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Infectious cystitis

Acute sinusitis

Neutropenia (low-risk)

Other specified pneumonia (Hospital-acquired pneumonia)

Bacterial cellulitis, erysipelas or lymphangitis

Chronic obstructive pulmonary disease with acute exacerbation

Peritonitis (mild-moderate)

Peritoneal abscess (mild-moderate)

Second choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Bacterial pneumonia (Community-acquired pneumonia - severe)

Osteomyelitis or osteitis

Bacterial infection of joint

Other specified prophylactic measures

Acute otitis media

Other indications

Bacterial infection of unspecified site

Multi-drug resistant Mycobacterium tuberculosis

Ampicillin

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
- Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Acute malnutrition in infants, children or adolescents (complicated) [children]

Peritonitis (mild-moderate)

Peritonitis (severe)

Peritoneal abscess (mild-moderate)

Peritoneal abscess (severe)

co-prescribed with gentamicin

Sepsis without septic shock

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

Azithromycin

Section

Watch group antibiotics

- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

Trachoma

Cholera

Cholera [children]

Paratyphoid fever

Chlamydia trachomatis

Typhoid fever

Yaws

co-prescribed with ceftriaxone

Gonococcal infection

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with cefixime

Gonococcal infection

Aztreonam

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified bacterial diseases

Bedaquiline

Section

Antituberculosis medicines

- Oral > Solid > tablet: 100 mg tablet; 20 mg tablet

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Benzathine benzylpenicillin

Section

Access group antibiotics

- Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection

Indications

First choice

Congenital syphilis [children]

Syphilis

Other indications

Bacterial infection of unspecified site

Benzylnicillin

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

Indications

First choice

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Congenital syphilis [children]

Syphilis

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with gentamicin

Sepsis without septic shock

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

Capreomycin

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Cefalexin

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid: 250 mg (as monohydrate)
- Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
- Oral > Solid > dispersible tablet: 125 mg; 250 mg

Indications

First choice

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Chronic obstructive pulmonary disease with acute exacerbation

Acute pharyngitis

Other indications

Bacterial infection of unspecified site

Cefazolin

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

First choice

Other specified prophylactic measures

Other specified prophylactic measures

Second choice

Bacterial infection of joint

Osteomyelitis or osteitis

Other indications

Surgical site infection

Cefepime

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

Other specified bacterial diseases

Cefiderocol

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Cefixime

Section

Watch group antibiotics

- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

Gonococcal infection

Cefotaxime

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

Bacterial meningitis

Inflammatory and other diseases of prostate (severe)

Acute pyelonephritis (severe)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Bacterial pneumonia (Community-acquired pneumonia - severe)

Peritoneal abscess (mild-moderate)

Peritoneal abscess (severe)

Other specified pneumonia (Hospital-acquired pneumonia)

Peritonitis (mild-moderate)

Peritonitis (severe)

Second choice

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Sepsis without septic shock

Bacterial infection of joint

Osteomyelitis or osteitis

Other indications

Bacterial infection of unspecified site

Ceftaroline

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

Other specified bacterial diseases

Ceftazidime

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

First choice

Endophthalmitis

Other indications

Pseudomonas aeruginosa resistant to other antibiotic

Ceftazidime + avibactam

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Ceftolozane + tazobactam

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

Other specified pneumonia (Hospital-acquired pneumonia)

Inflammatory and other diseases of prostate (severe)

Bacterial meningitis

Acute pyelonephritis (severe)

Paratyphoid fever

Gonococcal infection

Typhoid fever

Peritonitis (mild-moderate)

Peritonitis (severe)

Peritoneal abscess (mild-moderate)

Peritoneal abscess (severe)

Endophthalmitis

Bacterial pneumonia (Community-acquired pneumonia - severe)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with metronidazole

Necrotising fasciitis

Second choice

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Bacterial infection of joint

Sepsis without septic shock

Osteomyelitis or osteitis

Infectious gastroenteritis or colitis without specification of infectious agent

Other indications

Bacterial infection of unspecified site

Cefuroxime

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

Other specified prophylactic measures

Chloramphenicol

Section

Access group antibiotics

- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
- Oral > Liquid: 150 mg per 5 mL (as palmitate)
- Oral > Solid: 250 mg capsule

Indications

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

Ciprofloxacin

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid: 250 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Indications

First choice

Acute pyelonephritis (mild to moderate)

Infectious gastroenteritis or colitis without specification of infectious agent

Paratyphoid fever

Typhoid fever

Neutropenia (low-risk)

Inflammatory and other diseases of prostate (mild to moderate)

Second choice

Cholera

Cholera [children]

Peritonitis (mild-moderate)

Peritoneal abscess (mild-moderate)

Other indications

Bacterial infection of unspecified site

Clarithromycin

Section	Indications
Watch group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid ◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection ◦ Oral > Solid > dosage form: 500 mg; 250 mg ◦ Oral > Solid > dosage form: 500 mg	First choice co-prescribed with cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe) Second choice Acute pharyngitis co-prescribed with amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe) Other indications Helicobacter pylori associated gastric ulcer

Clindamycin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride) ◦ Oral > Solid: 150 mg (as hydrochloride) capsule ◦ Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection ◦ Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate) ◦ Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride) ◦ Oral > Solid: 150 mg (as hydrochloride)	First choice Necrotising fasciitis Second choice Bacterial infection of joint Osteomyelitis or osteitis Other indications Bacterial infection of unspecified site

Clofazimine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dosage form: 100 mg; 50 mg	Multi-drug resistant Mycobacterium tuberculosis
Antileprosy medicines ◦ Oral > Solid > dosage form: 100 mg; 50 mg	Leprosy

Cloxacillin

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
- Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
- Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

Indications

First choice

Osteomyelitis or osteitis

Bacterial infection of joint

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Sepsis without septic shock

Other indications

Bacterial infection of unspecified site

Colistin (injection)

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium)
- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Cycloserine

Section

Antituberculosis medicines

- Oral > Solid > dosage form: 250 mg; 125 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Dapsone

Section

Antileprosy medicines

- Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

Indications

Leprosy

Daptomycin

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

Indications

Other specified bacterial diseases

Delafloxacin

Section

Watch group antibiotics

- Parenteral > General injections > IV: 300 mg lyophilized powder for injection
- Oral > Solid: 450 mg

Indications

Methicillin resistant *Staphylococcus aureus*

Delamanid

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 25 mg
- Oral > Solid > tablet: 50 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Dicloxacillin

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for

Osteomyelitis or osteitis

Therapeutic equivalent to [cloxacillin](#) for

Bacterial infection of joint

Therapeutic equivalent to [cloxacillin](#) for

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Therapeutic equivalent to [cloxacillin](#) for

Sepsis without septic shock

Doxycycline

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
- Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
- Oral > Solid > dosage form: 100 mg (as hyclate)

Indications

First choice

Cholera

Chlamydia trachomatis

Second choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Cholera [children]

Chronic obstructive pulmonary disease with acute exacerbation

Other indications

Bacterial infection of unspecified site

Eravacycline

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg lyophilized powder for injection

Indications

Carbapenem resistant Enterobacterales

Erythromycin

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
- Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
- Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

Second choice

Therapeutic equivalent to clarithromycin for

Acute pharyngitis

Other indications

Bacterial infection of unspecified site

Ethambutol

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)

Indications

Other specified tuberculosis

Tuberculosis

Ethambutol + isoniazid

Section

Antituberculosis medicines

- Oral > Solid: 400 mg + 150 mg tablet

Indications

Tuberculosis

Ethambutol + isoniazid + pyrazinamide + rifampicin

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Indications

Tuberculosis

Ethambutol + isoniazid + rifampicin

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 150 mg tablet

Indications

Tuberculosis

Ethionamide

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 125 mg
- Oral > Solid > tablet: 250 mg

Indications

Tuberculous meningitis

Multi-drug resistant Mycobacterium tuberculosis

Fifth generation cephalosporins

Section

Reserve group antibiotics

- .

Indications

Other specified bacterial diseases

Flomoxef

Section

Watch group antibiotics

- Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified other antibiotic resistant Enterobacterales

Flucloxacillin

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for

Osteomyelitis or osteitis

Therapeutic equivalent to [cloxacillin](#) for

Bacterial infection of joint

Therapeutic equivalent to [cloxacillin](#) for

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Therapeutic equivalent to [cloxacillin](#) for

Sepsis without septic shock

Fosfomycin (injection)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Fourth generation cephalosporins

Section

Watch group antibiotics

- .

Indications

Other specified bacterial diseases

Gatifloxacin

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Gentamicin

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

Neonatal meningitis

Sepsis without septic shock

Sepsis without septic shock

Sepsis without septic shock

co-prescribed with amoxicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with ampicillin

Peritonitis (mild-moderate)

co-prescribed with ampicillin

Peritonitis (severe)

co-prescribed with ampicillin

Peritoneal abscess (mild-moderate)

co-prescribed with ampicillin

Peritoneal abscess (severe)

co-prescribed with ampicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with benzylpenicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with benzylpenicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Second choice

Gonococcal infection

Other specified prophylactic measures

Other indications

Bacterial infection of unspecified site

Imipenem + cilastatin

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection	Second choice Therapeutic equivalent to meropenem for Peritonitis (severe) Therapeutic equivalent to meropenem for Peritoneal abscess (severe) Therapeutic equivalent to meropenem for Neutropenia (high-risk) Other indications Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii Therapeutic equivalent to meropenem for Multi-drug resistant Mycobacterium tuberculosis
Antituberculosis medicines	

Imipenem + cilastatin + relebactam

Section	Indications
Reserve group antibiotics - Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection - Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection	Carbapenem resistant Enterobacterales Other specified other antibiotic resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa

Isoniazid

Section	Indications
Antituberculosis medicines - Parenteral > General injections > IV: 100 mg per mL - Oral > Solid > dispersible tablet: 100 mg (scored) - Oral > Solid > tablet: 100 mg; 300 mg	Other specified tuberculosis Tuberculosis

Isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg	Tuberculosis

Isoniazid + rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 50 mg + 75 mg ◦ Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg	Tuberculosis

Isoniazid + rifapentine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 300 mg + 300 mg tablet (scored)	Latent tuberculosis

Kanamycin (injection)

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

Levofloxacin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 100 mg ◦ Oral > Solid > tablet: 250 mg; 500 mg; 750 mg	Multi-drug resistant Mycobacterium tuberculosis

Linezolid

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 2 mg per mL in 300 mL bag ◦ Oral > Liquid: 100 mg per 5 mL powder for oral liquid ◦ Oral > Solid: 400 mg tablet; 600 mg tablet ◦ Oral > Solid > dispersible tablet: 150 mg ◦ Oral > Solid > tablet: 600 mg	Other specified bacterial diseases
	Methicillin resistant Staphylococcus aureus
	Vancomycin resistant Staphylococcus aureus
	Vancomycin resistant Enterococcus
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 150 mg (scored) ◦ Oral > Solid > tablet: 600 mg	Multi-drug resistant Mycobacterium tuberculosis

Meropenem

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Antituberculosis medicines

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Second choice

Neonatal meningitis

Peritonitis (severe)

Peritoneal abscess (severe)

Neutropenia (high-risk)

Multi-drug resistant *Mycobacterium tuberculosis*

Meropenem + vaborbactam

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Carbapenem resistant *Acinetobacter baumannii*

Meticillin

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for

Osteomyelitis or osteitis

Therapeutic equivalent to [cloxacillin](#) for

Bacterial infection of joint

Therapeutic equivalent to [cloxacillin](#) for

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Therapeutic equivalent to [cloxacillin](#) for

Sepsis without septic shock

Metronidazole

Section

Access group antibiotics

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg

Indications

First choice

Trichomoniasis

Intestinal infections due to *Clostridioides difficile*

Necrotising fasciitis

co-prescribed with cefazolin

Other specified prophylactic measures

co-prescribed with cefotaxime

Peritoneal abscess (mild-moderate)

co-prescribed with cefotaxime

Peritoneal abscess (severe)

co-prescribed with cefotaxime

Peritonitis (mild-moderate)

co-prescribed with cefotaxime

Peritonitis (severe)

co-prescribed with ceftriaxone

Peritoneal abscess (mild-moderate)

co-prescribed with ceftriaxone

Peritoneal abscess (severe)

co-prescribed with ceftriaxone

Peritonitis (mild-moderate)

co-prescribed with ceftriaxone

Peritonitis (severe)

Second choice

co-prescribed with ciprofloxacin

Peritoneal abscess (mild-moderate)

co-prescribed with ciprofloxacin

Peritonitis (mild-moderate)

Other indications

Bacterial infection of unspecified site

Moxifloxacin

Section

Antituberculosis medicines

- Oral > Solid > tablet: 400 mg
- Oral > Solid > dispersible tablet: 100 mg

Indications

Tuberculosis

Multi-drug resistant *Mycobacterium tuberculosis*

Nafcillin

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for

Osteomyelitis or osteitis

Therapeutic equivalent to [cloxacillin](#) for

Bacterial infection of joint

Therapeutic equivalent to [cloxacillin](#) for

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Therapeutic equivalent to [cloxacillin](#) for

Sepsis without septic shock

Nitrofurantoin

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL oral liquid
- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

First choice

Infectious cystitis

Ofloxacin

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Omadacycline

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 100 mg lyophilized powder for injection
- Oral > Solid: 300 mg

Indications

Methicillin resistant *Staphylococcus aureus*

Oxacillin

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for

Osteomyelitis or osteitis

Therapeutic equivalent to [cloxacillin](#) for

Bacterial infection of joint

Therapeutic equivalent to [cloxacillin](#) for

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Therapeutic equivalent to [cloxacillin](#) for

Sepsis without septic shock

Oxazolindinones

Section

Reserve group antibiotics

◦ .

Indications

Other specified bacterial diseases

P-aminosalicylate sodium

Section

Antituberculosis medicines

- Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution

Indications

Multi-drug resistant Mycobacterium tuberculosis

P-aminosalicylic acid

Section

Antituberculosis medicines

- Oral > Solid: 4 g granules in sachet

Indications

Multi-drug resistant Mycobacterium tuberculosis

Phenoxymethylpenicillin

Section

Access group antibiotics

- Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
- Oral > Solid: 250 mg (as potassium salt) tablet
- Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

First choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Periapical abscess without sinus

Acute pharyngitis

Other indications

Bacterial infection of unspecified site

Piperacillin + tazobactam

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

First choice

Neutropenia (high-risk)

Other specified pneumonia (Hospital-acquired pneumonia)

Peritonitis (severe)

Peritoneal abscess (severe)

co-prescribed with clindamycin

Necrotising fasciitis

Plazomicin

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg per 10 mL

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Polymyxin B (injection)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Carbapenem resistant *Acinetobacter baumannii*

Polymyxins

Section

Reserve group antibiotics

- .

Indications

Other specified bacterial diseases

Pretomanid

Section

Antituberculosis medicines

- Oral > Solid > tablet: 200 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Procaine benzylpenicillin

Section

Access group antibiotics

- Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

Indications

First choice

Congenital syphilis [children]

Second choice

Syphilis

Protionamide

Section

Antituberculosis medicines

- Oral > Solid > tablet: 250 mg (scored)

Indications

Therapeutic equivalent to [ethionamide](#) for

Multi-drug resistant *Mycobacterium tuberculosis*

Pyrazinamide

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 400 mg; 500 mg

Indications

Tuberculosis

Rifabutin

Section

Antituberculosis medicines

- Oral > Solid: 150 mg

Indications

Tuberculosis

Rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Liquid: 20 mg per mL ◦ Oral > Solid: 150 mg; 300 mg ◦ Parenteral > General injections > IV: 600 mg in vial powder for injection	Tuberculosis Other specified tuberculosis
Antileprosy medicines ◦ Oral > Liquid: 20 mg per mL ◦ Oral > Solid: 150 mg; 300 mg	Leprosy

Rifapentine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > tablet: 150 mg; 300 mg ◦ Oral > Solid > dispersible tablet: 150 mg	Tuberculosis Latent tuberculosis

Spectinomycin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection	Second choice Gonococcal infection Other indications Bacterial infection of unspecified site

Streptomycin (injection)

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial	Multi-drug resistant Mycobacterium tuberculosis

Sulfamethoxazole + trimethoprim

Section

Access group antibiotics

- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
- Oral > Solid > dispersible tablet: 100 mg + 20 mg

Indications

First choice

Infectious cystitis

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

Other indications

Bacterial infection of unspecified site

Tedizolid

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to [linezolid](#) for

Methicillin resistant *Staphylococcus aureus*

Therapeutic equivalent to [linezolid](#) for

Vancomycin resistant *Staphylococcus aureus*

Therapeutic equivalent to [linezolid](#) for

Vancomycin resistant *Enterococcus*

Terizidone

Section

Antituberculosis medicines

- Oral > Solid > capsule: 250 mg

Indications

Therapeutic equivalent to [cycloserine](#) for

Multi-drug resistant *Mycobacterium tuberculosis*

Tetracycline

Section

Access group antibiotics

- Oral > Solid: 250 mg (hydrochloride)

Indications

Bacterial infection of unspecified site

Tigecycline

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

Other specified bacterial diseases

Trimethoprim

Section

Access group antibiotics

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 100 mg; 200 mg

Indications

First choice

Infectious cystitis

Vancomycin

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
- Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Indications

First choice

Necrotising fasciitis

co-prescribed with [ceftazidime](#)

Endophthalmitis

co-prescribed with [ceftriaxone](#)

Endophthalmitis

Second choice

Intestinal infections due to *Clostridioides difficile*

Neutropenia (high-risk)

Other indications

Methicillin resistant *Staphylococcus aureus*